Welcome to our dedicated page for Arrowhead Research Corporation news (Ticker: ARWR), a resource for investors and traders seeking the latest updates and insights on Arrowhead Research Corporation stock.
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) is a leading clinical-stage biotechnology company dedicated to developing innovative medicines that address intractable diseases through gene silencing. The company utilizes an extensive array of RNA chemistries and efficient delivery systems to harness the power of RNA interference (RNAi) mechanisms. This approach allows for the rapid, deep, and durable knockdown of target genes, thereby reducing the production of specific proteins that cause diseases.
Arrowhead's groundbreaking therapies are at the forefront of genetic-based treatments, presenting potential life-changing solutions for patients. Notable among their technologies is the Targeted RNAi Molecule (TRiMTM) platform. This platform employs ligand-mediated delivery for tissue-specific targeting while maintaining structural simplicity. The TRiMTM platform is built upon over a decade of research in actively targeted drug delivery, offering advantages such as simplified manufacturing processes and enhanced specificity.
The company's diverse portfolio includes promising treatments for conditions such as Hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular diseases. Arrowhead is continuously engaged in advancing its clinical programs and forging strategic partnerships to bring its novel therapies to market.
With headquarters in Pasadena, California, Arrowhead Pharmaceuticals remains committed to transforming the landscape of genetic medicine and improving patient outcomes worldwide. Their dedication to scientific innovation and patient care positions them as a pivotal player in the biotechnology sector.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has submitted an application to commence a Phase 1/2a clinical trial for ARO-MMP7, an investigational RNA interference therapeutic targeting matrix metalloproteinase 7 (MMP7) for idiopathic pulmonary fibrosis (IPF). The trial aims to assess safety, tolerability, and pharmacokinetics in healthy volunteers and IPF patients. This initiative expands Arrowhead's clinical pipeline, which includes other lung disease candidates. The trial approval is pending from the local Ethics Committee and the New Zealand Medicines and Medical Devices Safety Authority.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced its fiscal Q3 results for the period ending June 30, 2022, revealing a revenue of $32.4 million, down from $45.9 million in Q3 2021. The operating loss increased to $72.9 million, compared to $31.9 million the previous year. Notably, the company published promising Phase 2 clinical results for fazirsiran, with 58% of patients showing fibrosis regression. Arrowhead also initiated clinical studies for ARO-MUC5AC and ARO-RAGE and expanded its team. Cash resources stand at $582.4 million.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) will host a webcast and conference call on August 4, 2022, at 4:30 p.m. ET to discuss its financial results for the fiscal 2022 third quarter ended June 30, 2022. Investors can access the live audio webcast on the Company's website. A replay will be available for 90 days.
Arrowhead develops innovative RNAi-based therapeutics targeting intractable diseases through gene silencing.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has approved inducement grants for 34 new employees on July 1, 2022. The grants comprise a total of 138,000 restricted stock units, with 70,000 units awarded to the new chief commercial officer, Tracie Oliver. These grants are outside the company's stockholder-approved equity incentive plans and will vest over four years. Arrowhead focuses on developing RNA interference-based therapies to treat severe diseases by silencing problematic genes.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has initiated dosing in two Phase 1/2a clinical trials for ARO-MUC5AC and ARO-RAGE, innovative RNA interference therapeutics targeting mucin production and inflammatory responses in lung diseases. ARO-MUC5AC-1001 and ARO-RAGE-1001 trials aim to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers and asthma patients. CEO Chris Anzalone highlighted this as a pivotal milestone in the company's mission to tackle difficult-to-drug targets in respiratory conditions.
Takeda (TAK) and Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced promising results from the Phase 2 AROAAT-2002 study of fazirsiran for liver disease due to alpha-1 antitrypsin deficiency (AATD). Key findings include a 58% fibrosis regression in treated patients, an 83% median reduction in Z-AAT accumulation in the liver, and a 69% reduction in histologic globule burden. Fazirsiran aims to tackle AATD's liver manifestations, with plans for a Phase 3 study on the horizon. The collaboration has received Breakthrough Therapy and Orphan Drug designations from the FDA.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) is set to participate in several key healthcare conferences in June 2022. Events include the Jefferies Healthcare Conference from June 8-10 and the Goldman Sachs 43rd Annual Global Healthcare Conference from June 13-16, both featuring presentations by Vincent Anzalone, Vice President Finance and Investor Relations.
Additionally, they will present at The International Liver Congress™ 2022, discussing significant studies related to chronic hepatitis B. Further details can be accessed through their Events and Presentations webpage.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) is hosting a pulmonary R&D Day in New York City to unveil its pipeline of RNA interference therapeutics targeting pulmonary diseases. Key presentations include ARO-MUC5AC, ARO-RAGE, and ARO-MMP7, aimed at treating muco-obstructive and inflammatory conditions. ARO-RAGE shows over 90% mRNA reduction in preclinical studies, while ARO-MUC5AC promises significant silencing of pathogenic expression. ARO-MMP7 targets idiopathic pulmonary fibrosis. The event will enhance confidence in upcoming clinical trials.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported strong financial results for Q2 FY2022, demonstrating a revenue increase to $151.8 million, up from $32.8 million in Q2 FY2021. The company achieved a net income of $44.4 million, or $0.41 per diluted share, compared to a loss of $26.8 million in the previous year. Key developments include the initiation of several clinical studies for its investigational RNA interference therapeutics, which target various conditions, alongside the formation of a joint venture in Greater China and the groundbreaking of a new manufacturing facility.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has commenced construction on a new drug manufacturing facility in Verona, WI, expected to span about 160,000 square feet, alongside a 125,000 square foot laboratory and office space. The company has been awarded $16 million in tax increment financing from Verona and $2.5 million in refundable income tax credits from the Wisconsin Economic Development Corporation. Completion of the lab is anticipated by 2023, while the manufacturing facility is expected to finish in 2024, aiming to support the development of innovative RNAi-based therapies.
FAQ
What is the current stock price of Arrowhead Research Corporation (ARWR)?
What is the market cap of Arrowhead Research Corporation (ARWR)?
What is the primary focus of Arrowhead Pharmaceuticals?
What is RNA interference (RNAi)?
What is the TRiMTM platform?
Which diseases does Arrowhead Pharmaceuticals address?
Where is Arrowhead Pharmaceuticals headquartered?
What are the latest developments at Arrowhead Pharmaceuticals?
How does Arrowhead's technology benefit patients?
What are some advantages of the TRiMTM platform?
Is Arrowhead publicly traded?
How can I invest in Arrowhead Pharmaceuticals?
